Mar. 2026

In March 2026, Qurgen reported that numbers of patients with advanced solid tumors had received mid-dose SON-DP treatment (2.0-4.5 mg/kg) for over 18 months. Sustained tumor size reduction was observed throughout the 18-month SON-DP treatment period in some of these patients. No teratoma formation was observed in any of these patients. These findings support a favorable safety profile of SON-DP based cell-conversion cancer therapy.